CAR-T Therapy: A Promising Cancer Treatment
DOI:
https://doi.org/10.54097/hset.v8i.1116Keywords:
Cancer, CAR-T, Blood Cancer, Clinical Application.Abstract
CAR-T therapy is a new clinical treatment option. It is the focus of an increasing number of researches, all of which suggested that it has a beneficial therapeutic effect on a variety of diseases, especially blood cancer. In this paper, clinic applications of CAR-T therapy for many diseases are listed, including B-cell acute lymphoblastic leukemia, Hepatitis B, and Human Immunodeficiency Virus. The differences between CAR-T therapy and other cancer treatments like tumor-infiltrating lymphocyte and T cell receptor therapy were discussed, standard biological medicines, and antibody-mediated anti-cancer drugs. The study also looks at the limitations and side-effects of CAR-T therapy, such as toxicity, and missing the target. The disadvantages, constraints, and options for improvement were also discussed in the paper. To summarize, CAR-T therapy has a good therapeutic function on some illnesses, although it is still in the experimental stage and is not commonly used in the clinic. In the near future, CAR-T therapy is likely to be used in a rising range of therapeutic therapies. In general, this paper can help get a better knowledge of CAR-T treatment, as well as a more exact comprehension of its future evolution.
Downloads
References
Sterner R C, Sterner R M. CAR-T therapy: current limitations and potential strategies [J]. Blood Cancer Journal, 2021, 11(4): 69.
Watanabe N, McKenna M K, Rosewell S, et al. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment [J]. Molecular Therapy, 2021, 29(2): 505-520.
Haslauer T, Greil R, Zaborsky N, et al. CAR T-Cell Therapy in Hematological Malignancies [J]. International Journal of Molecular Sciences, 2021, 22(16): 8996.
Lin H, Cheng J, Mu W, et al. Advances in Universal CAR-T therapy [J]. Frontiers in Immunology, 2021, 12: 744823.
Ramos C A, Heslop H E, Brenner M K. CAR-T therapy for Lymphoma [J]. Annual Review of Medicine, 2016, 67(1): 165-183.
Mohanty R, Chowdhury C, Arega S, et al. CAR T cell therapy: A new era for cancer treatment [J]. Oncology Reports, 42(6): 2183–2195.
Zhang Q, Ping J, Huang Z, et al. CAR-T therapy in Cancer: Tribulations and Road Ahead [J]. Journal of Immunology Research. 2020, 2020: e1924379.
Till B G, Jensen M C, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells [J]. Blood, 2008, 112(6): 2261-2271.
Fielding A K, Richards S M, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study [J]. Blood, 2007, 109(3): 944-950.
Singh A K, McGuirk J P. CAR T cells: continuation in a revolution of immunotherapy [J]. The Lancet. Oncology. 2020, 21(3): e168-e178.
Turtle C J, Hanafi L A, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells [J]. Science Translational Medicine, 2016, 8(355): 355ra116.
Strati P, Nastoupil L J, Fayad L E, et al. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection [J]. Blood, 2019, 133(26): 2800-2802.
Bupha-Intr O, Haeusler G, Chee L, et al. CAR-T therapy and infection: a review [J]. Expert Review of Anti-infective Therapy, 2021, 19(6): 749-758.
Abramson J S, Irwin K E, Frigault M J, et al. Successful anti-CD19 CAR-T-cell therapy in HIVinfected patients with refractory high-grade B-cell lymphoma [J]. Cancer, 2019, 125: 3692–3698.
Zhao Z, Chen Y, Francisco N M, et al. The application of CAR-T therapy in hematological malignancies: advantages and challenges [J]. Acta Pharmaceutica Sinica B, 2018, 8(4): 539-551.
Wang L, Yao R, Zhang L, et al. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity [J]. International Immunopharmacology, 2019, 70: 498-503.
Siddiqi H F, Staser K W, Nambudiri V E. Research Techniques Made Simple: CAR T-Cell Therapy [J]. Journal of Investigative Dermatology, 2018, 138(12): 2501-2504.e1.
Sridhar P and Petrocca F. Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy [J]. Cancers, 2017, 9(7): 92.
The difference between traditional cancer treatment and immune cell therapy [EB/OL]. Zhihu Column, 2022-11-22. [2022-03-15]. https://zhuanlan.zhihu.com/p/93115991.
Zhang Q, Ping J, Huang Z, et al. CAR-T therapy in Cancer: Tribulations and Road Ahead [J]. Journal of Immunology Research, 2020, 2020: e1924379.
Rohaan M W, van den Berg J H, Kvistborg P, et al. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option [J]. Journal for Immunotherapy of Cancer, 2018, 6(1): 102.
Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, et al. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape [J]. Frontiers in Immunology, 2020, 11: 1109.
Berg J H, Heemskerk B, Rooij N, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up [J]. Journal for Immunotherapy of Cancer, 2020, 8(2): e000848.
Tan E, Gakhar N, Kirtane K. TCR gene-engineered cell therapy for solid tumors [J]. Clinical Hematology, 2021, 34(3): 101285.
Zhang J and Wang L. The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review [J]. Technology in Cancer Research & Treatment. 2019;18: 1533033819831068.
Krishna S, Lowery F J, Copeland A R, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer [J]. Science, 2020, 370(6522): 1328-1334.
Hay K A, Hanafi L A, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy [J]. Blood, 2017, 130(21): 2295-2306.
Cameron J, Laïla-Aïcha H, Carolina B, et al. CD19 CAR-T cells of defined CD4(+): CD8(+) composition in adult B cell ALL patients [J]. Journal of Clinical Investigation, 2016, 126(6): 2123-2138.
Neelapu S, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nature reviews. Clinical Oncology, 2018, 15(1): 47-62.
Morgan R A, Yang J C, Kitano M, et al. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced with a Chimeric Antigen Receptor Recognizing ERBB2 [J]. MOLECULAR THERAPY, 2010,18(4):843-851.
Qualls D and Salles G. Optimizing CAR T cell therapy in lymphoma [J]. Hematological Oncology, 2021, 39: 104-112.
Gao Q, Dong X, Xu Q, et al. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy [J]. Cancer Medicine, 2019, 8: 4254-4264.
Fousek K, Watanabe J, Joseph S K, et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression [J]. Leukemia, 2021, 35: 75-89.
Saito S, Hasegawa A, Nagai M, et al. Mutated GM-CSF-Based CAR T-Cells Targeting CD116/CD131 Complexes Exhibit Enhanced Anti-Tumor Effects Against Acute Myeloid Leukemia [J]. Blood, 2020, 136(Supplement 1): 36-37.
Fasslrinner F, Arndt C, Koristka S, et al. Midostaurin abrogates CD33‐directed UniCAR and CD33‐CD3 bispecific antibody therapy in acute myeloid leukaemia [J]. British Journal of Haematology, 2019, 186(5): 735-740.
Wang H, Kaur G, Sankin A I, et al. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies [J]. Journal of Hematology & Oncology, 2019, 12(1): 1-20.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
